There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical, Inc. (RARE) and Moderna Inc (MRNA) with bullish sentiments.
Ultragenyx Pharmaceutical, Inc. (RARE)
Barclays analyst Gena Wang maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. on May 6 and set a price target of $89. The company’s shares opened today at $62.49.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 18.9% and a 49.3% success rate. Wang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, BioMarin Pharmaceutical Inc., and Precision BioSciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical, Inc. with a $74.63 average price target, implying a 19.4% upside from current levels. In a report issued on May 6, Cowen & Co. also maintained a Buy rating on the stock with a $79 price target.
See today’s analyst top recommended stocks >>
Moderna Inc (MRNA)
In a report released yesterday, Geoff Meacham from Barclays maintained a Buy rating on Moderna Inc, with a price target of $26. The company’s shares opened today at $23.50.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.3% and a 56.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Bausch Health Companies Inc.
Moderna Inc has an analyst consensus of Strong Buy, with a price target consensus of $28.83, representing a 22.7% upside. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $27 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
